2026-04-29T01:50:35Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/173282024-09-21T21:45:08Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud
author
Pinto-Medel, María Jesús
author
Oliver-Martos, Begoña
author
Urbaneja-Romero, Patricia
author
Hurtado-Guerrero, Isaac
author
Ortega-Pinazo, Jesús
author
Serrano-Castro, Pedro
author
Fernández, Óscar
author
Leyva, Laura
2024-01-23T20:13:01Z
2024-01-23T20:13:01Z
2017-08-18
http://hdl.handle.net/10668/11520
http://hdl.handle.net/20.500.12105/17328
28821874
10.1038/s41598-017-09301-2
2045-2322
Scientific reports
The alteration of DNA methylation patterns are a key component of disease onset and/or progression. Our objective was to evaluate the differences in Long Interspersed Nuclear Element-1 (LINE-1) methylation levels, as a surrogate marker of global DNA methylation, between multiple sclerosis (MS) patients and healthy controls. In addition, we assessed the association of LINE-1 methylation with clinical disease activity in patients treated with IFNbeta (IFNβ). We found that individuals with high levels of LINE-1 methylation showed 6-fold increased risk of suffering MS. Additionally, treated MS patients who bear high LINE-1 methylation levels had an 11-fold increased risk of clinical activity. Moreover, a negative correlation between treatment duration and percentage of LINE-1 methylation, that was statistically significant exclusively in the group of patients without clinical activity, was observed. Our data suggest that in MS patients, a slight global DNA hypermethylation occurs that may be related to the pathophysiology of the disease. In addition, global DNA methylation levels could play a role as a biomarker for the differential clinical response to IFNβ.
eng
Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment.
research article